Latest Breaking News On - Phil lhuilier - Page 1 : comparemela.com

CatalYm to Present Positive New Phase 2a Follow-up Data on GDF-15 Neutralizing Antibody Visugromab in Advanced NSCLC, Urothelial, and Hepatocellular Cancer at the 2024 ASCO Annual Meeting

Oral presentation in "Developmental Therapeutics-Immunotherapy" session on Sunday, June 2, 2024, at 11:30 AM CDT CatalYm today announced that positive new follow-up results from its ongoing "GDFATHER"

Mccormick placeUnited statesPhil lhuilierIgnacio melero bermejoCatalym gmbAlison opalkoTrophic communicationsOncology congressAmerican society of clinical oncologyTed human effector cell relocation phaseAmerican societyClinical oncologyAnnual meetingGrowth differentiationPresentation detailsUniversidad de navarra

CatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination with Neoadjuvant Immunotherapy in Treatment-naive Muscle Invasive Bladder Cancer Patients

CatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination with Neoadjuvant Immunotherapy in Treatment-naive Muscle Invasive Bladder Cancer Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Catalym gmbPhil lhuilierAndrea necchiPhil lhuillierTrophic communicationsGenitourinary medical oncologyRaffaele hospitalPrincipal investigatorPhill huillierChief executive officerTed human effectorRelocation phaseGrowth differentiationPhill huilier

CatalYm Presents Data at ESMO 2023 Expanding GDF-15 s Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation

CatalYm Presents Data at ESMO 2023 Expanding GDF-15 s Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Phil lhuilierCatalym gmbChristine schuberth wagnerNature communicationsTrophic communicationsEuropean society for medical oncologyEuropean societyMedical oncologyChief scientific officerTed human effector cell relocationGrowth differentiationPhill huilierStephanie mayAktien sie

CatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor of anti-PD-1 Resistance

CatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor of anti-PD-1 Resistance
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Christine schuberth wagnerCalaym gdfatherAlison opalkoPhil lhuilierCatalym gmbTrophic communicationsNature communicationsBusiness wireGrowth differentiationChief scientific officerTed human effector cell relocationTed human effector cell relocation phasePhill huilierDie experten

CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody Visugromab in Combination with Nivolumab at ASCO 2023

Oral presentation highlights first data from the GDFATHER-2a trial demonstrating lasting and confirmed responses (as per RECIST criteria) following treatment with visugromab and the anti-PD-1 inhibitor

Mecklenburg vorpommernUnited statesPhil lhuilierIgnacio melero bermejoPhil lhuillierStefan klotterCatalym gmbInternational coordinating investigator profAmerican society of clinical oncologyTrophic communicationsTed human effector cell relocation phaseAmerican societyClinical oncologyAnnual meetingGrowth differentiationEugen leo